CDKN2A and acute lymphoblastic leukemia: (41) suggested that CDKN2A/B deletions played an independent prognostic role in predicting the risk of relapse (DFS HR 2.621, P = 0.0054) and OS (HR 2.162, P = 0.014) in the adult Ph+ B-ALL population.